2013


To access this material please log in or register

Register Authorize
2013/№2

Resistant hypertension: new and irrevocably essential

Kobalava Zh. D., Shavarova E. K.

Keywords: hyperpiesis, treatment

DOI: 10.18087/rhj.2013.2.1817

  1. Wolf-Maier K, Cooper RS, Banegas JR et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA. 2003;289 (18):2363–2369.
  2. Turnbull F, Neal B, Ninomiya T et al. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ. 2008;336 (7653):1121–1123.
  3. Lewington S, Clarke R, Qizilbash N et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360 (9349):1903–1913.
  4. Adler AI, Stevens RJ, Manley SE et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int. 2003;63 (1):225–232.
  5. World Health Organization World Health Report 2002: Reducing Risks, Promoting Healthy Life, 2002 World Health Organization Geneva, Switzerland.
  6. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288 (23):2981–2997.
  7. Dahlof B, Devereux RB, Kjeldsen SE et al. Cardiovascular morbi­dity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE) a randomised trial against atenolol. Lancet. 2002;359 (9311):995–1003.
  8. Pepine CJ, Handberg EM, Rhonda M et al. A Calcium Antagonist vs a Non-Calcium Antagonist Hypertension Treatment Strategy for Patients With Coronary Artery Disease. The International Verapamil SR / Trandolapril Study (INVEST): A Randomized Controlled Trial. JAMA 2003;21 (290):2805–2861.
  9. Chobanian AV, Bakris GL, Black HR et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42 (6):1206–1252.
  10. Calhoun DA, Jones D, Textor S et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension. 2008;51 (6):1403–1419.
  11. Cushman WC, Ford CE, Cutler JA et al. Success and predictors of blood pressure control in diverse North American settings: the  antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich). 2002;4 (6):393–404.
  12. Kaplan NM. Resistant hypertension. J Hypertens. 2005;23 (8):1441–1444.
  13. Egan BM, Zhao Y, Axon RN et al. Uncontrolled and apparent treatment resistant hypertension in the U. S. 1988–2008. Circulation. 2011;124 (9):1046–1058.
  14. de la Sierra A, Segura J, Banegas JR et al. Clinical Features of 8295 Patients With Resistant Hypertension Classified on the Basis of Ambulatory Blood Pressure Monitoring. Hypertension. 2011;57 (5):898–902.
  15. Daugherty SL, Powers JD, Magid DJ et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation. 2012;125 (13):1635–1642.
  16. Viera AJ. Resistant hypertension. J Am Board Fam Med. 2012;25 (4):487–495.
  17. Gupta AK, Nasothimiou EG, Chang CL et al. Baseline predictors of resistant hypertension in the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT): a risk score to identify those at high-risk. J Hypertens. 2011;29 (10):2004–2013.
  18. Moser M, Setaro FJ. Resistant or Difficult-to-Control Hypertension. N Engl J Med. 2006;355 (4):385–392.
  19. Sarafidis PA, Bakris GL. State of hypertension management in the United States: confluence of risk factors and the prevalence of resistant hypertension. J Clin Hypertens (Greenwich). 2008;10 (2):130–139.
  20. Brown MA, Buddle ML, Martin A. Is resistant hypertension really resistant? Am J Hypertens. 2001;14 (12):1263–1269.
  21. Redon J, Campos C, Narciso ML et al. Prognostic value of ambulatory blood pressure monitoring in refractory hypertension: a prospective study. Hypertension. 1998;31 (2):712–718.
  22. Pierdomenico SD, Lapenna D, Bucci A et al. Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant, and true resistant hypertension. Am J Hypertens. 2005;18 (11):1422–1428.
  23. Caro JJ, Salas M, Speckman JL et al. Persistence with treatment for hypertension in actual practice. CMAJ. 1999;160 (1):31–37.
  24. Mazzaglia G, Mantovani LG, Sturkenboom MC et al. Patterns of persistence with antihypertensive medications in newly diagnosed hypertensive patients in Italy: a retrospective cohort study in primary care. J Hypertens. 2005;23 (11):2093–2100.
  25. Van Wijk BL, Klungel OH, Heerdink ER, de Boer A. Rate and determinants of 10‑year persistence with antihypertensive drugs. J Hypertens. 2005;23 (11):2101–2107.
  26. Vrijens B, Vincze G, Kristanto P et al. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ. 2008;336 (7653):1114–1117.
  27. Кобалава Ж. Д, Виллевальде С. В, Исикова Х. В. Повышение приверженности и мотивации к антигипертензивной терапии у больных артериальной гипертонией с помощью образовательных программ и рационального применения ингибитора ангиотензинпревращающего фермента периндоприла. Результаты исследования ПРИЗМА. Кардиология 2010;50 (11):17–26.
  28. Кобалава Ж. Д., Котовская Ю. В., Старостина Е. Г., Виллевальде С. В. от имени исследователей АРГУС-2. Проблемы взаимодействия врача и пациента и контроль артериальной гипертонии в России. Основные результаты Российской научно-практической программы АРГУС-2. Кардиология. 2007;47 (3):38–47.
  29. Johnson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med. 1994;121 (4):289–300.
  30. Graves JW, Bloomfield RL, Buckalew VM Jr. Plasma volume in resistant hypertension: guide to pathophysiology and therapy. Am J Med Sci. 1989;298 (6):361–365.
  31. Nishizaka MK, Pratt-Ubunama M, Zaman MA et al. Validity of plasma aldosterone-to-renin activity ratio in African American and white subjects with resistant hypertension. Am J Hypertens. 2005;18 (6):805–812.
  32. Pimenta E, Gaddam KK, Oparil S et al. Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial. Hypertension. 2009;54 (3):475–481.
  33. Dietary Guidelines for Americans, 2010. U. S. Department of Health and Human Services. Available at: http://www.cnpp.usda.gov / DGAs2010‑PolicyDocument.htm. Accessed Jan. 31, 2011.
  34. Yakovlevitch M, Black HR. Resistant hypertension in a tertiary care clinic. Arch Intern Med. 1991;151 (9):1786–1792.
  35. Garg JP, Elliott WJ, Folker A et al. Resistant hypertension revisited: a comparison of 2 university-based cohorts. Am J Hypertens. 2005;18 (5 Pt 1):619–626.
  36. Bramlage P, Pittrow D, Wittchen HU et al. Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled. Am J Hypertens. 2004;17 (10):904–910.
  37. Morris MJ. Cardiovascular and metabolic effects of obesity. Clin Exp Pharmacol Physiol. 2008;35 (4):416–419.
  38. Sarafidis PA. Obesity, insulin resistance and kidney disease risk: insights into the relationship. Curr Opin Nephrol Hypertens. 2008;17 (5):450–456.
  39. Wong C, Marwick TH. Obesity cardiomyopathy: pathogenesis and pathophysiology. Nat Clin Pract Cardiovasc Med. 2007;4 (8):436–443.
  40. Calhoun DA, Nishizaka MK, Zaman MA et al. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension. 2002;40 (6):892–896.
  41. Sarafidis PA, Bakris GL. Resistant hypertension. An overview of evaluation and treatment. J Am Coll Cardiol. 2008;52 (22):1749–1757.
  42. Taler SJ, Textor SC, Augustine JE. Resistant hypertension: comparing hemody-namic management to specialist care. Hypertension. 2002;39 (5):982–988.
  43. Jamerson K, Bakris GL, Dahlof B et al. Exceptional early blood pressure control rates: the ACCOMPLISH trial. Blood Press. 2007;16 (2):80–86.
  44. Black HR, Elliott WJ, Grandits G et al. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End points (CONVINCE) trial. JAMA. 2003;289 (16):2073–2082.
  45. Václavík J, Sedlák R, Plachy M et al. Addition of Spironolactone in Patients With Resistant Arterial Hypertension (ASPIRANT). A Randomized, Double-Blind, Placebo-Controlled Trial. Hyper­tension. 2011;57 (6):1069–1075.
  46. Frank M, Bobrie G, Azizi M et al. Superiority of low dose diuretics combination over renin-angiotensin blockers combination in resistant hypertension. J Hypertens. 2010;28: e276.
  47. Hypertension: clinical management of primary hypertension in adults. Abailable at: www.nice.org.uk / guidance / CG127.
  48. Wald DS, Law M, Morris JK et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med. 2009;122 (3):290–300.
  49. Hermida RC, Ayala DE, Mojon A, Fernandez JR. Influence of time of day of blood pressure-lowering treatment on cardiovascular risk in hypertensive patients with type 2 diabetes. Diabetes Care. 2011;34 (6):1270–1276.
  50. Bisognano JD, Bakris G, Nadim MK et al. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial. J Am Coll Cardiol. 2011;58 (7):765–773.
  51. Scheffers IJ, Kroon AA, Schmidli J et al. Novel baroreflex activation therapy in resistant hypertension: results of a European multi-center feasibility study. J Am Coll Cardiol. 2010;56 (15):1254–1258.
  52. Krum H, Schlaich M, Whitbourn R et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicenter safety and proof-of-principle cohort study. Lancet. 2009;373 (9671):1275–1281.
  53. Simplicity HTN-1 Investigators 2011. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out of 24 months. Hypertension. 2011;57 (5):911–917.
  54. Elser MD, Krum H, Sobotka PA et al. Symplicity HTN-2 Investigators. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet. 2010;376 (9756):1903–1909.
Kobalava Zh. D., Shavarova E. K. Resistant hypertension: new and irrevocably essential. Russian Heart Journal. 2013;12(2):123-132

To access this material please log in or register

Register Authorize
Ru En